

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10551151	
	Filing Date		2006-05-18	
	First Named Inventor	Prendergast		
	Art Unit	4173		
	Examiner Name	Christopher R. Stone		
	Attorney Docket Number	3882-P03161-US		

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10551151
Filing Date	2006-05-18
First Named Inventor	Prendergast
Art Unit	4173
Examiner Name	Christopher R. Stone
Attorney Docket Number	3882-P03161-US

/C.S./	1	MASUDA, M., et al., "Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction," J. Exp. Therap. Oncol., 2:350-359, (2002).	<input type="checkbox"/>
/C.S./	2	DATABASE BIOSIS [Online] LIU, J-K., "Cancer chemoprevention by tea polyphenols through modulating signal transduction pathways," Arch. Pharm. Res., 25(5):561-571, Biosciences Information Service, Philadelphia, PA, (October 2002). [ABSTRACT]	<input type="checkbox"/>
/C.S./	3	COVER, C.M., et al., "Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells," Cancer Res., 59:1244-1251, (Mar. 15, 1999).	<input type="checkbox"/>
/C.S./	4	JAKSE, R., et al., "A simple synthesis of aplysinopsin analogues by dimethylamine substitution in N,N-(dimethylamino) methyldene derivatives of five-membered heterocycles," Tetrahedron, 57:8395-8403, (2001).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Christopher Stone/	Date Considered	10/02/2008
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.